New Zealand markets closed

Ionis Pharmaceuticals, Inc. (IONS)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
43.95-0.71 (-1.59%)
As of 03:15PM EDT. Market open.
Currency in USD

Valuation measures4

Market cap (intra-day) 6.51B
Enterprise value 5.63B
Trailing P/E 122.59
Forward P/E 90.91
PEG ratio (5-yr expected) 25.70
Price/sales (ttm)8.12
Price/book (mrq)16.83
Enterprise value/revenue 7.15
Enterprise value/EBITDA -23.88

Trading information

Stock price history

Beta (5Y monthly) 0.40
52-week change 328.00%
S&P500 52-week change 329.57%
52-week high 354.44
52-week low 334.32
50-day moving average 346.84
200-day moving average 345.26

Share statistics

Avg vol (3-month) 31.2M
Avg vol (10-day) 3923.59k
Shares outstanding 5145.75M
Implied shares outstanding 6145.75M
Float 8144.53M
% held by insiders 10.86%
% held by institutions 1101.03%
Shares short (15 Mar 2024) 49.67M
Short ratio (15 Mar 2024) 46.79
Short % of float (15 Mar 2024) 47.83%
Short % of shares outstanding (15 Mar 2024) 46.63%
Shares short (prior month 15 Feb 2024) 49.06M

Dividends & splits

Forward annual dividend rate 4N/A
Forward annual dividend yield 4N/A
Trailing annual dividend rate 30.00
Trailing annual dividend yield 30.00%
5-year average dividend yield 4N/A
Payout ratio 40.00%
Dividend date 3N/A
Ex-dividend date 4N/A
Last split factor 2N/A
Last split date 3N/A

Financial highlights

Fiscal year

Fiscal year ends 31 Dec 2023
Most-recent quarter (mrq)31 Dec 2023

Profitability

Profit margin -46.50%
Operating margin (ttm)4.79%

Management effectiveness

Return on assets (ttm)-7.51%
Return on equity (ttm)-76.34%

Income statement

Revenue (ttm)787.65M
Revenue per share (ttm)5.50
Quarterly revenue growth (yoy)113.60%
Gross profit (ttm)N/A
EBITDA -319.22M
Net income avi to common (ttm)-366.29M
Diluted EPS (ttm)-2.56
Quarterly earnings growth (yoy)N/A

Balance sheet

Total cash (mrq)2.34B
Total cash per share (mrq)16.04
Total debt (mrq)1.45B
Total debt/equity (mrq)375.90%
Current ratio (mrq)5.90
Book value per share (mrq)2.68

Cash flow statement

Operating cash flow (ttm)-307.51M
Levered free cash flow (ttm)-159.99M